Catheter Precision Amends Charter to Change Name to Flyte Aviation and Approves Reverse Split

Catheter Precision, Inc. has filed a Current Report on Form 8-K detailing several corporate actions approved by its stockholders during the Annual Meeting held on September 30, 2026. The filing confirms that the Company has amended its Amended and Restated Certificate of Incorporation to change its name from Catheter Precision, Inc. to Flyte Aviation, Inc., and to effect a 1-for-10 reverse stock split.

The reverse stock split is scheduled to become effective at 12:01 a.m. Eastern Time on October 5, 2026. At this time, every 10 shares of Common Stock will be reclassified and combined into one share. The Company anticipates that trading under the new name and the new trading symbol "VJET" will commence on the NYSE American on a split-adjusted basis at the opening of trading on October 5, 2026. The Common Stock has been assigned a new CUSIP number, 74933X 807, which will become effective at the split.

Following the reverse split, the number of issued and outstanding shares of Common Stock is expected to decrease from approximately 21,019,874 to approximately 2,101,987. The authorized capital stock will remain unchanged at 500 million shares of Common Stock and 10 million shares of preferred stock. The split will be applied uniformly to all stockholders, and no fractional shares will be issued; instead, holders of fractional shares will receive a pro rata portion of the net proceeds from the aggregation and sale of those shares.

In addition to the name change and split, the filing reports the results of the Annual Meeting. Stockholders approved a plan to reincorporate the Company from the State of Delaware to the State of Nevada. The stockholders also approved an amendment to the 2023 Equity Incentive Plan to increase the number of shares reserved for issuance by 5,000,000 shares. Furthermore, stockholders approved a one-time repricing of outstanding stock options, adjusting the exercise price to $0.152 per share based on the closing price on September 30, 2026. David A. Jenkins was elected as a Class II director to serve a three-year term expiring at the 2029 Annual Meeting.